These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 19047117)

  • 1. A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer.
    Dickler MN; Rugo HS; Eberle CA; Brogi E; Caravelli JF; Panageas KS; Boyd J; Yeh B; Lake DE; Dang CT; Gilewski TA; Bromberg JF; Seidman AD; D'Andrea GM; Moasser MM; Melisko M; Park JW; Dancey J; Norton L; Hudis CA
    Clin Cancer Res; 2008 Dec; 14(23):7878-83. PubMed ID: 19047117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study.
    Cohen EE; Davis DW; Karrison TG; Seiwert TY; Wong SJ; Nattam S; Kozloff MF; Clark JI; Yan DH; Liu W; Pierce C; Dancey JE; Stenson K; Blair E; Dekker A; Vokes EE
    Lancet Oncol; 2009 Mar; 10(3):247-57. PubMed ID: 19201650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer.
    Chambers SK; Clouser MC; Baker AF; Roe DJ; Cui H; Brewer MA; Hatch KD; Gordon MS; Janicek MF; Isaacs JD; Gordon AN; Nagle RB; Wright HM; Cohen JL; Alberts DS
    Clin Cancer Res; 2010 Nov; 16(21):5320-8. PubMed ID: 21041183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study.
    Lubner SJ; Mahoney MR; Kolesar JL; Loconte NK; Kim GP; Pitot HC; Philip PA; Picus J; Yong WP; Horvath L; Van Hazel G; Erlichman CE; Holen KD
    J Clin Oncol; 2010 Jul; 28(21):3491-7. PubMed ID: 20530271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma.
    Sathornsumetee S; Desjardins A; Vredenburgh JJ; McLendon RE; Marcello J; Herndon JE; Mathe A; Hamilton M; Rich JN; Norfleet JA; Gururangan S; Friedman HS; Reardon DA
    Neuro Oncol; 2010 Dec; 12(12):1300-10. PubMed ID: 20716591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity.
    Montagna E; Cancello G; Bagnardi V; Pastrello D; Dellapasqua S; Perri G; Viale G; Veronesi P; Luini A; Intra M; Calleri A; Rampinelli C; Goldhirsch A; Bertolini F; Colleoni M
    Clin Breast Cancer; 2012 Jun; 12(3):207-14. PubMed ID: 22520733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer.
    Ko AH; Venook AP; Bergsland EK; Kelley RK; Korn WM; Dito E; Schillinger B; Scott J; Hwang J; Tempero MA
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1051-7. PubMed ID: 20130876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.
    Seto T; Kato T; Nishio M; Goto K; Atagi S; Hosomi Y; Yamamoto N; Hida T; Maemondo M; Nakagawa K; Nagase S; Okamoto I; Yamanaka T; Tajima K; Harada R; Fukuoka M; Yamamoto N
    Lancet Oncol; 2014 Oct; 15(11):1236-44. PubMed ID: 25175099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors.
    Lin CC; Calvo E; Papadopoulos KP; Patnaik A; Sarantopoulos J; Mita AC; Preston GG; Mita MM; Rodon J; Mays T; Yeh IT; O'Rourke P; Takimoto CH; Dancey JE; Chen H; Tolcher AW
    Cancer Chemother Pharmacol; 2009 May; 63(6):1065-71. PubMed ID: 18795291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE).
    Bullock KE; Petros WP; Younis I; Uronis HE; Morse MA; Blobe GC; Zafar SY; Gockerman JP; Lager JJ; Truax R; Meadows KL; Howard LA; O'Neill MM; Broadwater G; Hurwitz HI; Bendell JC
    Cancer Chemother Pharmacol; 2011 Feb; 67(2):465-74. PubMed ID: 21079958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer.
    Herbst RS; Johnson DH; Mininberg E; Carbone DP; Henderson T; Kim ES; Blumenschein G; Lee JJ; Liu DD; Truong MT; Hong WK; Tran H; Tsao A; Xie D; Ramies DA; Mass R; Seshagiri S; Eberhard DA; Kelley SK; Sandler A
    J Clin Oncol; 2005 Apr; 23(11):2544-55. PubMed ID: 15753462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer.
    Philip PA; Mahoney MR; Holen KD; Northfelt DW; Pitot HC; Picus J; Flynn PJ; Erlichman C
    Cancer; 2012 May; 118(9):2424-30. PubMed ID: 21953248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/imatinib: a phase I/II trial.
    Hainsworth JD; Spigel DR; Sosman JA; Burris HA; Farley C; Cucullu H; Yost K; Hart LL; Sylvester L; Waterhouse DM; Greco FA
    Clin Genitourin Cancer; 2007 Dec; 5(7):427-32. PubMed ID: 18272024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer.
    Traina TA; Rugo HS; Caravelli JF; Patil S; Yeh B; Melisko ME; Park JW; Geneus S; Paulson M; Grothusen J; Seidman AD; Fornier M; Lake D; Dang C; Robson M; Theodoulou M; Flombaum CD; Norton L; Hudis CA; Dickler MN
    J Clin Oncol; 2010 Feb; 28(4):628-33. PubMed ID: 19841327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual EGFR inhibition in combination with anti-VEGF treatment: a phase I clinical trial in non-small cell lung cancer.
    Falchook GS; Naing A; Hong DS; Zinner R; Fu S; Piha-Paul SA; Tsimberidou AM; Morgan-Linnell SK; Jiang Y; Bastida C; Wheler JJ; Kurzrock R
    Oncotarget; 2013 Jan; 4(1):118-27. PubMed ID: 23435217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia.
    Nimeiri HS; Oza AM; Morgan RJ; Friberg G; Kasza K; Faoro L; Salgia R; Stadler WM; Vokes EE; Fleming GF; ; ;
    Gynecol Oncol; 2008 Jul; 110(1):49-55. PubMed ID: 18423560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastatic colorectal cancer.
    Meyerhardt JA; Stuart K; Fuchs CS; Zhu AX; Earle CC; Bhargava P; Blaszkowsky L; Enzinger P; Mayer RJ; Battu S; Lawrence C; Ryan DP
    Ann Oncol; 2007 Jul; 18(7):1185-9. PubMed ID: 17483115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
    Gianni L; Romieu GH; Lichinitser M; Serrano SV; Mansutti M; Pivot X; Mariani P; Andre F; Chan A; Lipatov O; Chan S; Wardley A; Greil R; Moore N; Prot S; Pallaud C; Semiglazov V
    J Clin Oncol; 2013 May; 31(14):1719-25. PubMed ID: 23569311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma.
    Jackman DM; Kindler HL; Yeap BY; Fidias P; Salgia R; Lucca J; Morse LK; Ostler PA; Johnson BE; Jänne PA
    Cancer; 2008 Aug; 113(4):808-14. PubMed ID: 18543326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer.
    Bukowski RM; Kabbinavar FF; Figlin RA; Flaherty K; Srinivas S; Vaishampayan U; Drabkin HA; Dutcher J; Ryba S; Xia Q; Scappaticci FA; McDermott D
    J Clin Oncol; 2007 Oct; 25(29):4536-41. PubMed ID: 17876014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.